用于靶向治疗前列腺癌的[镥]-PSMA-617：神奇子弹？ - Suppr | 超能文献

[Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?

作者信息

Paganelli Giovanni, De Giorgi Ugo

机构信息

Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRST) IRCCS, 47014 Meldola, Italy.

Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRST) IRCCS, 47014 Meldola, Italy.

出版信息

Lancet Oncol. 2018 Jun;19(6):725-726. doi: 10.1016/S1470-2045(18)30268-7. Epub 2018 May 8.

DOI:10.1016/S1470-2045(18)30268-7

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?用于靶向治疗前列腺癌的[镥]-PSMA-617：神奇子弹？

Lancet Oncol. 2018 Jun;19(6):725-726. doi: 10.1016/S1470-2045(18)30268-7. Epub 2018 May 8.

2

[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer.[镥]-PSMA-617放射性核素治疗转移性去势抵抗性前列腺癌患者。

Lancet Oncol. 2018 Aug;19(8):e371. doi: 10.1016/S1470-2045(18)30410-8.

3

[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer.[镥]-PSMA-617放射性核素疗法治疗转移性去势抵抗性前列腺癌患者

Lancet Oncol. 2018 Aug;19(8):e372. doi: 10.1016/S1470-2045(18)30488-1.

4

[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author's reply.[镥]-PSMA-617放射性核素治疗转移性去势抵抗性前列腺癌患者——作者回复

Lancet Oncol. 2018 Aug;19(8):e373. doi: 10.1016/S1470-2045(18)30534-5.

5

Re: [Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study.回复：[镥]-PSMA-617放射性核素治疗转移性去势抵抗性前列腺癌患者（镥PSMA试验）：一项单中心、单臂、2期研究。

Eur Urol. 2019 Mar;75(3):536-537. doi: 10.1016/j.eururo.2018.11.005. Epub 2018 Nov 15.

6

[Lu]PSMA-617 radionuclide therapy shows promise.[卢]PSMA - 617放射性核素疗法显示出前景。

Nat Rev Urol. 2018 Aug;15(8):468. doi: 10.1038/s41585-018-0029-6.

7

Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.Bi-PSMA-617靶向α放射性核素疗法治疗转移性去势抵抗性前列腺癌

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.

8

[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.[44Sc]Sc-PSMA-617 示踪剂在转移性去势抵抗性前列腺癌患者中的生物分布和剂量学研究。

Clin Nucl Med. 2018 May;43(5):323-330. doi: 10.1097/RLU.0000000000002003.

9

Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.镥-前列腺特异性膜抗原 617 放射性配体治疗后恢复激素反应的转移性前列腺癌。

Clin Nucl Med. 2016 Jul;41(7):572-3. doi: 10.1097/RLU.0000000000001200.

10

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.177Lu-PSMA-DKFZ-617重复放射性配体治疗去势抵抗性转移性前列腺癌的治疗反应和副作用

Oncotarget. 2016 Mar 15;7(11):12477-88. doi: 10.18632/oncotarget.7245.

引用本文的文献

1

Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of Ac-PSMA (Prostate-Specific Membrane Antigen).转移性去势抵抗性前列腺癌（mCRPC）患者的靶向α治疗：锕-前列腺特异性膜抗原（Ac-PSMA）的预测剂量测定与毒性建模

Front Oncol. 2020 Nov 5;10:531660. doi: 10.3389/fonc.2020.531660. eCollection 2020.

2

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.使用放射性标记的前列腺特异性膜抗原（PSMA）抑制剂对前列腺癌进行靶向α治疗：核医学领域的变革者。

Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):247-267. eCollection 2018.